EORTC/LinkedIn
Apr 19, 2025, 07:39
The first patient has been enrolled in the SPRINT study – EORTC
EORTC – European Organisation for Research and Treatment of Cancer shared a post on LinkedIn:
“We’re excited to announce that the first patient has been randomised in the SPRINT study!
The patient was enrolled at Inselspital in Bern, under the supervision of Principal Investigator Professor Hossein Hemmatazad.
The EORTC-2387 SPRINT study is the first pan-European Trial within Cohorts (TwiCs) focused on patients with oligometastatic disease and is part of the OligoCare cohort within the E2RADIatE platform.
SPRINT is supported by the Rising Tide Group Tide Foundation. E²RADIatE receives support from Walgreens Boots Alliance.”
More posts featuring EORTC.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 25, 2025, 16:04
Aug 25, 2025, 15:59
Aug 25, 2025, 15:59
Aug 25, 2025, 15:56